CVBT Announces Positive Results for Diabetic Wound Healing in Preclinical Studies

CardioVascular BioTherapeutics (CVBT) has announced that its preclinical animal studies showed positive results for its drug candidate Cardio Vascu-Grow for wound healing in diabetic mice.

CVBT said the preclinical data showed Cardio Vascu-Grow materially improved the healing rate of open wounds in diabetic mice as compared to the control groups. At defined times, up to a six-fold increase in the healing rate was observed.

The market for wound healing includes diabetic, bedridden and elderly patients that suffer from wounds, open sores and diabetic ulcers, CVBT said. According to the U.S. Healthcare Finance Administration, approximately 2.5 to 3.0 million patients a year suffer from these maladies. Annual treatment costs in the U.S. alone are in the range of $5 billion to $7 billion, the company said.